바이오정보모아 (BioJungboMoa) — ADC · Antibody

8428프로그램 40FDA 승인

143오늘 방문

4,777누적 방문

7303갱신 대기 S–CData Tier S/A/B차세대 →Insight 1032HER2 breast 4683Antibody 2713CGT →Psoriasis →NSCLC 40FDA 승인

피드 Data Tier 차세대 Insight

Prednisolone (Prednisolone)

Healthy · Solid Tumor

#SolidTumor#ADC#Approved#인기#항체약물접합체+3

효능 ORR 85.5%임상시험 132상태 RECRUITING

ADCBHotBiologicPharmacyclics LLC.Phase 3

Ibrutinib (Ibrutinib)

Metastatic Renal Cell Carcinoma; Advanced Urothelial Carcinoma · Non-Hodgkin Lymphoma

#Non-HodgkinLymphoma#ADC#Phase3#인기#항체약물접합체+5

효능 ORR 93.9%임상시험 126상태 ACTIVE

AntibodyCHotBeiGeneVedotin, Tislelizumab, and …Phase 2

Tislelizumab (Tislelizumab)

Locally Recurrent Colorectal Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase2#인기#항체+5

효능 ORR 37.1%임상시험 125상태 RECRUITING

AntibodyAHotMerck KGaAvedotin (EV) was the most c…Phase 3

Avelumab (Avelumab)

Non Small Cell Lung Cancer; Colorectal Cancer · Locally Advanced or Metastatic Urothelia

#LocallyAdvancedorMetastaticUroth#Antibody#Phase3#인기#항체+5

효능 ORR 74%임상시험 123상태 ACTIVE

AntibodyBHotInnoventvedotin (an HER2-targeted a…Phase 3

Sintilimab (Sintilimab)

Advanced Hepatocellular Carcinoma (HCC) · HER2

#HER2#Antibody#Phase3#인기#항체+5

효능 ORR 4.5%임상시험 123상태 RECRUITING

ADCBHotBiologicstaleGlaxoSmithKlinePreclinical

23-valent (Pneumococcal Vaccine, Polyvalent, Pneumococcal Vaccine, Polyvalent (23-valent))

HIV Infections; Hepatitis B · HIV Infections

#HIVInfections#ADC#Preclinical#인기#항체약물접합체+3

효능 ORR 94.99%임상시험 121상태 ACTIVE

ADCSHotBiologicRocheDM1 via butelase-1 with ABD…Approved

trastuzumab (Herceptin, Trastuzumab Emtansine)

HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer · Metastatic Salivary Gland Carcinoma

#MetastaticSalivaryGlandCarcinoma#ADC#Approved#인기#항체약물접합체+5

효능 ORR 80%임상시험 119상태 RECRUITING

ADCBHotBiologicstaleSeagenPreclinical

recombinant (Brentuximab vedotin, Brentuximab vedotin (recombinant))

Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma · CD30

#CD30#ADC#Preclinical#인기#항체약물접합체+3

효능 ORR 89.5%임상시험 118상태 ACTIVE

AntibodyCHotstaleAstraZenecaPhase 2

durvalumab + tremelimumab (STRIDE, STRIDE (durvalumab + tremelimumab))

Advanced Unresectable Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#인기#항체+5

효능 ORR 37.4%임상시험 118상태 RECRUITING

AntibodySHOTFDACuratedFDABiologicEli LillyApproved

tirzepatide (Mounjaro / Zepbound, Mounjaro, Zepbound, LY3298176)

Type 2 diabetes, chronic weight management · GLP-1 / GIP receptor

#GLP-1GIPreceptor#Antibody#Approved#FDA승인#바이오정보모아추천+5

효능 HbA1c ↓2.4%임상시험 117상태 APPROVED

ADCCHotBiologicstaleAdcendo ApSPhase 2

ADC (Antibody-drug conjugate, Antibody-drug conjugate (ADC))

Metastatic Soft Tissue Sarcoma; Unresectable Soft Tissue Sarcoma · Metastatic Soft Tissue Sarcoma

#MetastaticSoftTissueSarcoma#ADC#Phase2#인기#항체약물접합체+3

효능 ORR 31.2%임상시험 114상태 RECRUITING

CGTCHotBiologicstaleThomas Martin, MDPhase 1

Chimeric Antigen Receptor T cells (CAR-T, Chimeric Antigen Receptor T cells, Chimeric Antigen Receptor T cells (CAR-T) Targeting BCMA)

Multiple Myeloma; Recurrent Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#인기#세포유전치료+5

효능 ORR 97.1%임상시험 113상태 DISCONTINUED

AntibodyBHotBiologicstaleRocheDM1 via butelase-1 with ABD…Phase 1

HERCEPTIN (MAB HER 2, MAB HER 2 (HERCEPTIN))

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase1#인기#항체+5

효능 ORR 91.2%임상시험 113상태 RECRUITING

AntibodyBHotRochederuxtecan plus fluoropyrim…Phase 2

trastuzumab (Herceptin, FLOT, 5-FU, leucovorin, docetaxel, oxaliplatin, 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab)

Adenocarcinoma of the Gastroesophageal Junction; Adenocarcinoma of the Stomach · Adenocarcinoma of the Gastroesophageal J

#AdenocarcinomaoftheGastroesophag#Antibody#Phase2#인기#항체+5

효능 ORR 61%임상시험 112상태 ACTIVE

AntibodyAHotstaleMerckvedotin plus pembrolizumab …Phase 2

pembrolizumab (KEYTRUDA®, KEYTRUDA® (pembrolizumab))

Solid Tumors · Solid Tumor, Adult

#SolidTumorAdult#Antibody#Phase2#인기#항체+5

효능 ORR 93.5%임상시험 111상태 RECRUITING

AntibodyBHotstaleMerckPhase 2

pembrolizumab or nivolumab (The combination of radiotherapy with anti-PD1, The combination of radiotherapy with anti-PD1 (pembrolizumab or nivolumab))

Melanoma · Melanoma

#Melanoma#Antibody#Phase2#인기#항체+3

효능 ORR 56.1%임상시험 110상태 ACTIVE

ADCBHotBiologicstaleRochePhase 2

Lyophilized (Polatuzumab vedotin, Polatuzumab vedotin (Lyophilized))

Lymphoma · Lymphoma

#Lymphoma#ADC#Phase2#인기#항체약물접합체+2

효능 ORR 100%임상시험 108상태 ACTIVE

ADCBHotBiologicstaleDaiichi SankyoPhase 1

DP (DS-8201a, DS-8201a (DP))

Advanced Solid Tumors · Advanced Solid Tumors

#AdvancedSolidTumors#ADC#Phase1#인기#항체약물접합체+2

효능 ORR 69.7%임상시험 107상태 ACTIVE

ADCCHotBiologicstaleRochePhase 2

PV (Polatuzumab vedotin, Polatuzumab vedotin (PV))

Diffuse Large B-cell Lymphoma · Diffuse Large B-cell Lymphoma

#DiffuseLargeB-cellLymphoma#ADC#Phase2#인기#항체약물접합체+2

효능 ORR 100%임상시험 106상태 DISCONTINUED

AntibodyBHotstaleBeiGeneVedotin, Tislelizumab, and …Phase 1

BGB-A317 (Tislelizumab, Tislelizumab (BGB-A317))

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase1#인기#항체+5

효능 ORR 68.3%임상시험 105상태 RECRUITING

AntibodySHOTFDACuratedFDABiologicEli LillyApproved

lebrikizumab (Ebglyss, Lilly)

Atopic dermatitis · IL-13

#IL-13#Antibody#Approved#FDA승인#바이오정보모아추천+5

효능 ORR 75%임상시험 104상태 APPROVED

ADCCHotBiologicstaleHoffmann-La RochePhase 2

Luteinizing Hormone-Releasing Hormone (LHRH, Luteinizing Hormone-Releasing Hormone, Luteinizing Hormone-Releasing Hormone (LHRH) Agonists)

Ovarian Cancer · Ovarian Cancer

#OvarianCancer#ADC#Phase2#인기#항체약물접합체+2

효능 ORR 31%임상시험 104상태 RECRUITING

AntibodyCHotstaleXin-Hua XuPhase 2

AK104 (Cadonilimab, Cadonilimab (AK104))

Non-small Cell Lung Cancer · Leptomeningeal Metastasis

#LeptomeningealMetastasis#Antibody#Phase2#인기#항체+5

임상시험 101상태 RECRUITING

AntibodyCstalePENG YUANPhase 2

QL1706 (Iparomlimab and Tuvonralimab, Iparomlimab and Tuvonralimab (QL1706))

Platinum Resistant Ovarian Cancer; Platinum Refractory Epithelial Ovarian Cancer · Gastric Cancer (GC)

#GastricCancerGC#Antibody#Phase2#인기#항체+5

임상시험 97상태 RECRUITING

ADCCBiologicstaleEMD SeronoSN-38 for the treatment of …Phase 2

TMZ (Temozolomide, Temozolomide (TMZ))

Childhood Cancer; Childhood Solid Tumor · Advanced Solid Malignancies

#AdvancedSolidMalignancies#ADC#Phase2#인기#항체약물접합체+5

효능 ORR 40%임상시험 97상태 RECRUITING

3 / 142 페이지

← 이전 다음 →

전체 8,428개 프로그램 보기

갱신 기록 없음 · 14일 주기 · 방문 143 / 4,777

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

빠른 검색 · 이슈 태그

Prednisolone (Prednisolone)

Ibrutinib (Ibrutinib)

Tislelizumab (Tislelizumab)

Avelumab (Avelumab)

Sintilimab (Sintilimab)

23-valent (Pneumococcal Vaccine, Polyvalent, Pneumococcal Vaccine, Polyvalent (23-valent))

trastuzumab (Herceptin, Trastuzumab Emtansine)

recombinant (Brentuximab vedotin, Brentuximab vedotin (recombinant))

durvalumab + tremelimumab (STRIDE, STRIDE (durvalumab + tremelimumab))

tirzepatide (Mounjaro / Zepbound, Mounjaro, Zepbound, LY3298176)

ADC (Antibody-drug conjugate, Antibody-drug conjugate (ADC))

Chimeric Antigen Receptor T cells (CAR-T, Chimeric Antigen Receptor T cells, Chimeric Antigen Receptor T cells (CAR-T) Targeting BCMA)

HERCEPTIN (MAB HER 2, MAB HER 2 (HERCEPTIN))

trastuzumab (Herceptin, FLOT, 5-FU, leucovorin, docetaxel, oxaliplatin, 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab)

pembrolizumab (KEYTRUDA®, KEYTRUDA® (pembrolizumab))

pembrolizumab or nivolumab (The combination of radiotherapy with anti-PD1, The combination of radiotherapy with anti-PD1 (pembrolizumab or nivolumab))

Lyophilized (Polatuzumab vedotin, Polatuzumab vedotin (Lyophilized))

DP (DS-8201a, DS-8201a (DP))

PV (Polatuzumab vedotin, Polatuzumab vedotin (PV))

BGB-A317 (Tislelizumab, Tislelizumab (BGB-A317))

lebrikizumab (Ebglyss, Lilly)

Luteinizing Hormone-Releasing Hormone (LHRH, Luteinizing Hormone-Releasing Hormone, Luteinizing Hormone-Releasing Hormone (LHRH) Agonists)

AK104 (Cadonilimab, Cadonilimab (AK104))

QL1706 (Iparomlimab and Tuvonralimab, Iparomlimab and Tuvonralimab (QL1706))

TMZ (Temozolomide, Temozolomide (TMZ))

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

Prednisolone (Prednisolone)

Ibrutinib (Ibrutinib)

Tislelizumab (Tislelizumab)

Avelumab (Avelumab)

Sintilimab (Sintilimab)

23-valent (Pneumococcal Vaccine, Polyvalent, Pneumococcal Vaccine, Polyvalent (23-valent))

trastuzumab (Herceptin, Trastuzumab Emtansine)

recombinant (Brentuximab vedotin, Brentuximab vedotin (recombinant))

durvalumab + tremelimumab (STRIDE, STRIDE (durvalumab + tremelimumab))

tirzepatide (Mounjaro / Zepbound, Mounjaro, Zepbound, LY3298176)

ADC (Antibody-drug conjugate, Antibody-drug conjugate (ADC))

Chimeric Antigen Receptor T cells (CAR-T, Chimeric Antigen Receptor T cells, Chimeric Antigen Receptor T cells (CAR-T) Targeting BCMA)

HERCEPTIN (MAB HER 2, MAB HER 2 (HERCEPTIN))

trastuzumab (Herceptin, FLOT, 5-FU, leucovorin, docetaxel, oxaliplatin, 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab)

pembrolizumab (KEYTRUDA®, KEYTRUDA® (pembrolizumab))

pembrolizumab or nivolumab (The combination of radiotherapy with anti-PD1, The combination of radiotherapy with anti-PD1 (pembrolizumab or nivolumab))

Lyophilized (Polatuzumab vedotin, Polatuzumab vedotin (Lyophilized))

DP (DS-8201a, DS-8201a (DP))

PV (Polatuzumab vedotin, Polatuzumab vedotin (PV))

BGB-A317 (Tislelizumab, Tislelizumab (BGB-A317))

lebrikizumab (Ebglyss, Lilly)

Luteinizing Hormone-Releasing Hormone (LHRH, Luteinizing Hormone-Releasing Hormone, Luteinizing Hormone-Releasing Hormone (LHRH) Agonists)

AK104 (Cadonilimab, Cadonilimab (AK104))

QL1706 (Iparomlimab and Tuvonralimab, Iparomlimab and Tuvonralimab (QL1706))

TMZ (Temozolomide, Temozolomide (TMZ))

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

Prednisolone (Prednisolone)

Ibrutinib (Ibrutinib)

Tislelizumab (Tislelizumab)

Avelumab (Avelumab)

Sintilimab (Sintilimab)

23-valent (Pneumococcal Vaccine, Polyvalent, Pneumococcal Vaccine, Polyvalent (23-valent))

trastuzumab (Herceptin, Trastuzumab Emtansine)

recombinant (Brentuximab vedotin, Brentuximab vedotin (recombinant))

durvalumab + tremelimumab (STRIDE, STRIDE (durvalumab + tremelimumab))

tirzepatide (Mounjaro / Zepbound, Mounjaro, Zepbound, LY3298176)

ADC (Antibody-drug conjugate, Antibody-drug conjugate (ADC))

Chimeric Antigen Receptor T cells (CAR-T, Chimeric Antigen Receptor T cells, Chimeric Antigen Receptor T cells (CAR-T) Targeting BCMA)

HERCEPTIN (MAB HER 2, MAB HER 2 (HERCEPTIN))

trastuzumab (Herceptin, FLOT, 5-FU, leucovorin, docetaxel, oxaliplatin, 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab)

pembrolizumab (KEYTRUDA®, KEYTRUDA® (pembrolizumab))

pembrolizumab or nivolumab (The combination of radiotherapy with anti-PD1, The combination of radiotherapy with anti-PD1 (pembrolizumab or nivolumab))

Lyophilized (Polatuzumab vedotin, Polatuzumab vedotin (Lyophilized))

DP (DS-8201a, DS-8201a (DP))

PV (Polatuzumab vedotin, Polatuzumab vedotin (PV))